News & Events

Results of Operations and Financial Condition.

Regulation FD Disclosure Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced on April 9, 2026, that its Board of Directors has declared a cash dividend in the amount of $0.72 per share of common stock. The dividend will be payable on June 11, 2026, to stockholders of record as of the close of business on May 29, 2026 . A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated by reference herein.

Entry into a Material Definitive Agreement. On March 20, 2026 (the “Closing Date”), Labcorp Holdings Inc. (the “Company”), as parent guarantor, and Laboratory Corporation of America Holdings (“LCAH”), as borrower, entered into a Term Loan Credit Agreement (the “Credit Agreement”) with Wells Fargo Bank, National Association (“Wells Fargo”), as administrative agent, Wells Fargo Securities, LLC, as joint lead arranger and sole bookrunner, PNC Capital Markets LLC, as joint lead arranger, PNC Bank…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Labcorp Holdings Inc. (the “Company”) today announced that on February 6, 2026, the Company’s Board of Directors (the “Board”) appointed John H. Sampson, M.D., Ph.D., as a member of the Board, effective February 9, 2026. In connection with Dr. Sampson’s appointment, the Board has appointed Dr. Sampson to the Quality and Compliance Committee. Dr. Sa…

Entry into a Material Definitive Agreement. On January 28, 2026, Labcorp Holdings Inc. (the “Company”) amended its receivables purchase agreement (as amended, the “Receivables Purchase Agreement”) by entering into the Second Amendment to the Receivables Purchase Agreement (the “RPA Amendment”), among Labcorp Receivables LLC (“Labcorp Receivables”), Laboratory Corporation of America Holdings, PNC Bank, National Association, as administrative agent and the other parties thereto and acknowledged…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 9, 2025, Mark Schroeder, the Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer of Labcorp Holdings Inc. (the “Company”), notified the Company of his intention to retire, effective on April 1, 2026. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant h…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers As previously disclosed, on January 4, 2023, Paul Kirchgraber, Senior Advisor to the CEO, and former EVP and CEO of Labcorp’s Drug Development business segment, informed Laboratory Corporation of America Holdings (“Labcorp”) that he intended to depart Labcorp upon the completion of the spin-off of Fortrea Holdings Inc. in order to pursue other oppor…

Regulation FD Disclosure On August 8, 2023, Laboratory Corporation of America Holdings (the Company) entered into accelerated share repurchase agreements (collectively, the ASR Agreements) with Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC (collectively, the Financial Institutions) to repurchase approximately $1.0 billion in the aggregate of the Company’s common stock (Common Stock), as part of the Company’s Common Stock repurchase program. Matthews South, Inc. served as capital market…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers In connection with an internal organizational restructuring in preparation for the previously announced, planned spin-off of the Clinical Development and Commercialization Services business of Labcorp, on May 4, 2023, Labcorp announced that Brian J. Caveney, the current Executive Vice President, President, Diagnostics and Chief Medical Officer of La…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers In connection with an internal organizational restructuring in preparation for the previously announced, planned spin-off of the Clinical Development and Commercialization Services business of Labcorp, on May 4, 2023, Labcorp announced that Mark S. Schroeder, the current Executive Vice President, and President, Diagnostics Laboratory Operations and…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers In connection with an internal organizational restructuring in preparation for the previously announced, planned spin-off of the Clinical Development and Commercialization Services business of Laboratory Corporation of America ® Holdings (“Labcorp”), on May 4, 2023, Labcorp announced that Brian J. Caveney, the current Executive Vice President, Presi…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers In connection with an internal organizational restructuring in preparation for the previously announced, planned spin-off of the Clinical Development and Commercialization Services business of Laboratory Corporation of America ® Holdings (“Labcorp”), on May 4, 2023, Labcorp announced that Mark S. Schroeder, the current Executive Vice President, and…

Regulation FD Disclosure. On December 13, 2021, Laboratory Corporation of America Holdings (the “Company”) entered into accelerated share repurchase agreements (collectively, the “ASR Agreements”) with Goldman Sachs & Co. LLC and Barclays Bank PLC (collectively, the “Financial Institutions”) to repurchase approximately $1.0 billion in the aggregate of the Company’s common stock (“Common Stock”), as part of the Company’s Common Stock repurchase program. Under the ASR Agreements, the Company wi…